Pomegra
Apogee Therapeutics (APGE) trades at $131.75, off 0.6%, just below AbbVie's $135.11 cash offer as merger arbitrageurs position for a Q3 2026 close.
- AbbVie agreed to buy Apogee Therapeutics for $135.11 a share in a $10.9B all-cash deal announced June 22, 2026.
- APGE surged 47% on the announcement and holds near $131.75, a roughly $3.36 discount to the deal price, with the spread reflecting standard close-execution risk.
- Zumilokibart, Apogee's IL-13 antibody, offers less frequent dosing than Dupixent and is the central strategic rationale for AbbVie's largest acquisition in more than five years.
Lead
Apogee Therapeutics (APGE) closed at $132.55 on June 22, 2026 — a 47% single-session gain — after AbbVie (ABBV) announced a $10.9 billion all-cash takeover priced at $135.11 per share. On June 23, APGE edged back to $131.75, a decline of 0.6% on the day, leaving shares approximately $3.36 below the acquisition price. The transaction, AbbVie's largest in more than five years, centers on Apogee's late-stage antibody pipeline for atopic dermatitis and asthma.What Happened
AbbVie and Apogee disclosed a definitive merger agreement on June 22, 2026, under which AbbVie will acquire all outstanding Apogee shares for $135.11 in cash. The offer represents a premium of approximately 49% to APGE's unaffected closing price of roughly $90.38 on June 18. Both boards voted unanimously to approve the transaction, and key Apogee investors entered voting agreements that reduce shareholder-rejection risk. Closing is targeted for the third quarter of 2026, pending antitrust clearances under the Hart-Scott-Rodino Act and an Apogee stockholder vote.
Market Reaction and Merger Arbitrage
After opening sharply higher on June 22 and closing at $132.55, APGE slipped to $131.75 the following session — a post-47% pop decline of 0.6% — widening the gross merger arbitrage spread to roughly $3.36, or approximately 2.5% of the deal price. At an assumed late-September close, the implied annualized gross return on the spread approaches 7%, before financing costs.
The residual discount to deal price reflects standard close-of-merger uncertainty: antitrust review timelines, the possibility of a shareholder vote shortfall, or any material adverse change that could activate deal termination provisions. None of the initial deal disclosures indicated unusual complications on any of those fronts.
AbbVie shares declined modestly on the announcement — a typical market response to a large cash acquisition — as investors weighed the $10.9 billion price tag against AbbVie's debt capacity and near-term earnings trajectory.Strategic Context
The acquisition addresses a clear strategic gap for AbbVie. Humira (adalimumab), the company's flagship immunology product, has faced sustained revenue compression since U.S. biosimilar competition began, pressuring AbbVie to source replacement growth from dealmaking and newer assets Skyrizi and Rinvoq.
Apogee's lead compound, zumilokibart (APG777), is a subcutaneous, half-life-extended monoclonal antibody targeting interleukin-13 (IL-13), a cytokine implicated in atopic dermatitis and asthma. Its extended half-life is designed to allow less frequent dosing than existing IL-4/IL-13 inhibitors — a differentiation play aimed directly at Dupixent (dupilumab), the blockbuster co-developed by Sanofi and Regeneron Pharmaceuticals, which generated more than $13 billion in global sales in 2024.
Phase 2 APEX Part B data, released alongside the deal announcement, showed strong 16-week skin-clearance outcomes for zumilokibart in moderate-to-severe atopic dermatitis. Apogee had already announced plans to begin a registrational Phase 3 program in the second half of 2026; that program will proceed under AbbVie's ownership once the transaction closes.
A second program, APG273, pairs zumilokibart with APG333, an anti-TSLP antibody, targeting asthma — extending the potential commercial footprint into the respiratory space. AbbVie characterized the combined franchise as having "mega-blockbuster" peak sales potential.
Separately, Apogee had secured up to $1.3 billion in largely non-dilutive financing from Blackstone to fund the Phase 3 pathway through potential commercialization, reducing near-term capital risk for AbbVie post-close.
